Results 101 to 110 of about 122,325 (212)

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source

Prevalence of Transfusion-Transmitted Viruses Among Blood Donors at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia (2019-2024). [PDF]

New Microbes New Infect
Sindi N, Alzahrani OA, Alamoudi LM, Sait AM, Alqahtani MA, Mufrrih SA, Alqahtani IM, Hakami NY, Sait FM, Alqahtani M, Mufrrih M.   +10 more
europepmc   +1 more source

Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa (EFA) is an ultra–extended half‐life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real‐world data remain important to better characterize PK profiles across patient ...
Laurent Sattler, Agathe Herb, Léa Pierre, Jordan Wimmer, Manon Dolt, Olivier Feugeas, Dominique Desprez   +6 more
wiley   +1 more source

A Framework for Emergency Department-Integrated Hepatitis C Test-and-Treat in the United States. [PDF]

J Viral Hepat
Graham SS.
europepmc   +1 more source

UK Infected Blood Inquiry–An Historical Appraisal

Haemophilia, EarlyView.
ABSTRACT Introduction This appraisal considers the 2018 UK Infected Blood Inquiry and its Report (2024) in the context of the history of haemophilia treatment developments over the past fifty‐five years, and the tragic impacts of the AIDS pandemic. Aim The paper appraises the conduct and findings of the IBI and its Report in relation to HIV and AIDS ...
Christopher A. Ludlam
wiley   +1 more source

Characterization of the virus-host RNA-RNA interactome across important human pathogenic RNA viruses. [PDF]

PLoS Pathog
Damas ND, Seemann SE, Costa R, Krambrich J, Fossat N, Rivera-Rangel LR, Fahnøe U, Nielsen L, Gorodkin J, Bukh J, Scheel TKH.   +10 more
europepmc   +1 more source

Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study

Haemophilia, EarlyView.
ABSTRACT Background Despite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia‐related pain.
Ilenia Lorenza Calcaterra, Sofia Donnarumma, Guido D'Errico, Carmine De Luca, Chiara Caputo, Paola Ciciola, Ernesto Cimino, Matteo Di Minno   +7 more
wiley   +1 more source

From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe. [PDF]

Lancet Reg Health Eur
Picchio CA, Nicolàs A, Duffell E, Martró E, Vickerman P, Dudareva S, Lens S, Vanderlinden A, Cabezas J, Forns X, Gill US, Razavi-Shearer D, Aghemo A, Halford R, Vanwolleghem T, Matthews PC.   +15 more
europepmc   +1 more source

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study

British Journal of Haematology, EarlyView.
Luca Arcaini, Michele Merli, Sara Rattotti, Maria Elena Nizzoli, Vittoria Tarantino, Chiara Consoli, Annalisa Talami, Roberta Murru, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Guilherme Duffles, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J. M. Ferreri, Caterina Stelitano, Elsa Pennese, Marzia Varettoni, Emilia Cappello, Gianmarco Favrin, Martina La Fauci, Luigi Marcheselli, Marco Paulli, Stefano Luminari   +25 more
wiley   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source